Neuroendocrine tumor of unknown primary
PDF (Español (España))
HTML (Español (España))
صندلی اداری سرور مجازی ایران Decentralized Exchange

How to Cite

1.
Gray Torres SV. Neuroendocrine tumor of unknown primary . Rev.méd.sinerg. [Internet]. 2023Mar.1 [cited 2024Jul.3];8(3):e988. Available from: https://revistamedicasinergia.com/index.php/rms/article/view/988

Abstract

Neuroendocrine Tumors(NET) are a heterogeneous grupo f tumors that ar formed in cells capable to produce hormones in the blood which act as a resulto f a signal from the nervous system. Such tumors may produce more hormones than usual which causes diferente symptoms. They can develop in any organ of the body although its presentation in the digestive tract, pancreas and  is more frequent bronchopulmonary tract. 

Approximately 65% belong to the digestive tract, 25% to the bronchial pulmonary tract and 10% are considered as others. There is a diversity of clinical characteristics, which is associated with a low incidence, it is estimated at 6.98 new cases per 100,000 habitants, this makes them difficult to diagnose since in many cases the symptoms are either specific or found by chance, but in more than half of the cases the diagnosis is late when the disease is already advanced, so interdisciplinary management is necessary. It is estimated the approximately more than 12,000 people in the United States are diagnosed with NET each year, 175,000 people are living with this disease. In Spain, 3,220 new cases are diagnosed each year and 17,000 patients are affected. 

https://doi.org/10.31434/rms.v8i3.988

Keywords

neuroendocrine tumors. fine needle biopsy. immnunohistochemistry. nuclear magnetic resonance. computed tomography of the thorax. abdomen and pelvis.
PDF (Español (España))
HTML (Español (España))

References

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. NCCN. [Guideline] [Consultado en Mayo 24, 2022]. Disponible en: http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.Version 1.2022 - May 23, 2022;Accessed:

Physician Data Query (PDQ) .Carcinoma of Unknown Primary: Treatment. National Cancer Institute. [Internet][Consultado en 25/05/2014].Disponible en: www.cancer.gov/cancertopics/pdq/treatment/unknownprimary/HealthProfessional on June 25, 2014.

American Cancer Society. Cancer Facts and Figures 2016. Atlanta, Ga. 2016.[Internet][Consultado en 2016] Disponible en: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2016.html

American Cancer Society. Cancer Facts and Figures 2017.Atlanta,Ga.[Internet] [Consultado en 2017].Disponible en: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Occult primary. Version 3.2014.[Internet] [Consultado Junio 25, 2014].Disponible en: www.nccn.org

Greco FA, Hainsworth JD. Cancer of unknown primary site. En: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa.Lippincott Williams & Wilkins; 2011.p.2033-2051.

Varadachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785.

Jerusalem G, Rorive A, Ancion G, et al. Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaging investigations. Ann Oncol. 2006;17 Suppl 10:168-176.

Mintzer DM, Warhol M, Martin AM, et al. Cancer of unknown primary: changing approaches. A multidisciplinary case presentation from the Joan Karnell Cancer Center of Pennsylvania Hospital. Oncologist. 2004;9:330-338.

Seve P, Sawyer M, Hanson J, et al. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site. Cancer. 2006;106.2058-2066.

Neuroendocrine Tumor Research Foundation and Dasari A, et al.: Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright (c) 2023 Array

Downloads

Download data is not yet available.
فروشگاه اینترنتی صندلی اداری جوراب افزایش قد ژل افزایش قد صندلی اداری vpn for android